Novel Technologies And Innovations For Prevention And Treatment Of Infectious Diseases | 58132
Journal of Infectious Diseases & Therapy
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Bacterial antimicrobial resistance in both the medical and agricultural fields has become a serious problem worldwide. During
the last 15 years, our laboratories have worked toward the identification of probiotic candidates for poultry which can actually
displace Salmonella and other enteric pathogens which have colonized the gastrointestinal tract of chicks and turkeys, indicating that
selection of therapeutically efficacious probiotic cultures with marked performance benefits in poultry is possible and that defined
cultures can sometimes provide an attractive alternative to conventional antimicrobial therapy. Our studies have been focused on
specific pathogen reduction, performance under commercial conditions and effects on both idiopathic and defined enteritis. We have
also confirmed that selected heat-resistant spore-forming Bacillus species can markedly reduce Salmonella and Clostridium when
administered in very high numbers and we have developed a novel and simple technique for obtaining cultured Bacillus spore counts,
providing a cost-effective feed-stable inclusion in commercial poultry diets. In order to select even more effective isolates, we are still
currently focused on the mechanistic action of the Lactobacillus probiotic previously developed as well as new Bacillus candidates.
Current indications are that mechanism of action involves rapid activation of innate host immune mechanisms, providing an exciting
possibility for identification of vastly superior and more potent probiotics. In this presentation, we summarize the safety and efficacy
of individual monocultures for prophylactic and/or therapeutic efficacy against Salmonella infections under both laboratory and field
conditions as well as the development of a novel, cost-effective, feed-stable direct fed microbials (DFM) with potential for widespread
utilization and improved production, delivery and clinical efficacy for animal use.
G Tellez is affiliated to the University of Arkansas, USA.